Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
Level 5 - mechanism / opinion, no new human data
Narrative review and methodological commentary interpreting phase 2 trial data
PubMed 36891463 · doi:10.1212/CPJ.0000000000200127
What was done
The authors reviewed the background, structure, and clinical interpretation of the Integrated Alzheimer's Disease Rating Scale (iADRS)—a composite cognitive and functional trial endpoint—using data from the phase 2 TRAILBLAZER-ALZ randomized trial of donanemab in early symptomatic Alzheimer disease over 76 weeks.
What was found
In the TRAILBLAZER-ALZ study, donanemab slowed disease progression measured by the iADRS by 32% at 18 months compared with placebo (p = 0.04). Applying thresholds for clinically meaningful decline, treatment with donanemab was estimated to delay reaching that threshold by approximately 6 months.
Why it matters
This commentary outlines how composite endpoints like the iADRS can capture combined cognitive and functional trajectories and translate statistical slowing into estimated delays in clinical worsening.
Limits
This is a narrative review and methodological explanation rather than a primary trial report or systematic review. The abstract provides no sample size, confidence intervals, or safety outcomes, and relies on findings from a single phase 2 trial.
Cited by
- supports Eli Lilly's monoclonal antibody donanemab was shown to slow the decline of Alzheimer's disease by 32%.